Sanofi Pre-Tax Income 2012-2026 | SNY
Sanofi annual/quarterly pre-tax income history and growth rate from 2012 to 2026. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Sanofi pre-tax income for the quarter ending March 31, 2026 was $2.344B, a 3.12% increase year-over-year.
- Sanofi pre-tax income for the twelve months ending March 31, 2026 was $7.057B, a 12.43% decline year-over-year.
- Sanofi annual pre-tax income for 2025 was $6.986B, a 3.61% decline from 2024.
- Sanofi annual pre-tax income for 2024 was $7.248B, a 6.38% decline from 2023.
- Sanofi annual pre-tax income for 2023 was $7.742B, a 29.5% decline from 2022.
|
Sanofi Annual Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2025 | $6,986 |
| 2024 | $7,248 |
| 2023 | $7,742 |
| 2022 | $10,981 |
| 2021 | $9,226 |
| 2020 | $15,768 |
| 2019 | $3,161 |
| 2018 | $5,202 |
| 2017 | $6,251 |
| 2016 | $6,283 |
| 2015 | $5,822 |
| 2014 | $7,618 |
| 2013 | $6,114 |
| 2012 | $7,558 |
| 2011 | $7,408 |
|
Sanofi Quarterly Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,344 |
| 2025-12-31 | $-1,005 |
| 2025-09-30 | $4,103 |
| 2025-06-30 | $1,615 |
| 2025-03-31 | $2,273 |
| 2024-12-31 | $435 |
| 2024-09-30 | $3,852 |
| 2024-06-30 | $1,499 |
| 2024-03-31 | $1,462 |
| 2023-12-31 | $-142 |
| 2023-09-30 | $3,304 |
| 2023-06-30 | $1,943 |
| 2023-03-31 | $2,636 |
| 2022-12-31 | $4,244 |
| 2022-09-30 | $2,692 |
| 2022-06-30 | $1,442 |
| 2022-03-31 | $2,602 |
| 2021-09-30 | $3,487 |
| 2021-06-30 | |
| 2021-03-31 | $2,379 |
| 2020-09-30 | $2,861 |
| 2020-03-31 | $2,174 |
| 2019-09-30 | $2,282 |
| 2019-03-31 | $1,539 |
| 2018-03-31 | $1,479 |
| 2017-12-31 | $824 |
| 2017-09-30 | $2,234 |
| 2017-06-30 | $1,447 |
| 2017-03-31 | $1,746 |
| 2016-12-31 | $1,205 |
| 2016-09-30 | $2,396 |
| 2016-06-30 | $1,539 |
| 2016-03-31 | $1,144 |
| 2015-09-30 | $2,058 |
| 2015-06-30 | $2,083 |
| 2014-06-30 | $1,580 |
| 2013-06-30 | $705 |
| 2012-06-30 | $1,901 |
| 2012-03-31 | $2,736 |
| 2011-12-31 | $1,092 |
| 2011-09-30 | $3,133 |
| 2011-06-30 | $1,433 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |